Loading clinical trials...
Loading clinical trials...
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA
Conditions
Interventions
Ritlecitinib higher dose
Ritlecitinib lower dose
+1 more
Locations
80
United States
California Dermatology & Clinical Research Institute
Encinitas, California, United States
University of California - Irvine
Irvine, California, United States
Investigational Drug Service - Rady Children's Hospital-San Diego
San Diego, California, United States
University of California, San Diego/Rady Children's Hospital-San Diego;
San Diego, California, United States
Southern California Clinical Research
Santa Ana, California, United States
Children's Hospital Colorado
Aurora, Colorado, United States
Start Date
July 31, 2025
Primary Completion Date
April 20, 2027
Completion Date
May 18, 2027
Last Updated
March 30, 2026
NCT07152119
NCT07029828
NCT07200128
NCT06562894
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions